

MSTS Newsletter

Volume 26, Fall 2020

Inside this Issue

President's Report1	Thank You Donors!4	Research Committee9
Treasurer's Report2	Evidence Based Medicine Committee. . .5	Virtual Annual Meeting10
Musculoskeletal Tumor Registry2	Practice Management Committee5	Coding Course11
MSTS Executive Committee2	Sarcoma Strong Corner7	Webinar Series14

President's Report – Joel Mayerson, MD, FAOA, FAAOS



Joel Mayerson, MD

As summer turns towards fall, I wanted to give you some updates about our society as the MSTS leadership has had a busy year even though we have not been able to discuss it

in person. As we are all acutely aware the world continues in an uncertain time and in uncharted waters. The MSTS has been affected greatly but still remains strong due to its volunteers. The time and effort that all of our volunteers have put forth on behalf of the MSTS is inspiring and on behalf of our leadership I want to thank each and every one you for your dedication to making the MSTS a leading source of musculoskeletal oncology education and advocacy.

As we had previously discussed in our Spring newsletter, MSTS Specialty Day in 2021 was planned to be presented March 13 in San Diego. However, as most of you are aware the AAOS decided to move their meeting to August 31 - September 4, 2021 putting Specialty Day on the Saturday of the holiday weekend. The MSTS Leadership team discussed this prospect and decided to pull out in 2021 because we felt the attendance would be poor. We are currently hoping that we will add this

content to our 2021 event, but we have not yet booked our 2021 venue since we do not want to expose the Society to additional expenses should the event need to be canceled or be poorly attended. The Executive Committee will continually assess this and determine what is in the best interest of the society and our membership. We appreciate the patience of Drs. Pietro Ruggieri and Nicholas Bernthal as we wait to determine when this fantastic content will be presented.

This year's MSTS meeting will be our first virtual annual meeting. The meeting will be free for members and \$25.00 for non-members as we are doing everything we can to keep costs down for our members. The Annual Meeting will occur from 12:00 pm to 3:00 pm (Central Time) on Friday October 9. We will have 1 hour of podium presentations that will be led by the Annual Program Meeting Committee to showcase the best of all submissions with a short period for discussion of each presentation. After the podium presentations, we will have 2 Orthopedic Product Theaters presented by ONKOS Surgical and Daiichi-Sankyo International. These two companies have continued to support the MSTS at the Diamond level and we are extremely thankful for their support. We will then have a one-hour business meeting that will as always include updates for all of our MSTS committee and highlighted by Dr. Carol Morris' incoming Presidential

Address. I am excited to hear about all of her plans for the MSTS in the upcoming year. We will also be having three-hour coding course from Karen Zupko Associates to teach us about all of the updates coming in 2021 for E/M coding as well as give us updates for CPT coding. This course has been outstanding in the past and we anticipate it will be again this year. Since it is being given digitally, it is important that you [pre-register](#) for this as we will need to mail you the course workbook, so you are able to follow along with the speaker. We will not be able to provide a copy after the deadline as it will not reach you prior to the course. You will be receiving more information soon with exact timing. New this year the Education Committee will be presenting webinars on a bimonthly basis to update our membership about current challenges in musculoskeletal oncology practice. Look for notices for dates soon.

The MSTS Executive Committee has been extremely busy working on a new management mechanism as we will no longer be managed by the AAOS. We have reached an agreement with the Ruth Jackson Orthopedic Society to keep Kerri Mink as our Executive Director and Deborah Meyer as our Society Coordinator on a permanent basis and we will be continuing to share them with the RJOS. We have secured a lease that we will share with the Shoulder and Elbow Society, Hip Society, Knee Society
Continued on page 6

MSTS Headquarters

Treasurer's Report – Michelle Ghert, MD, FRCSC

The first half of 2020 was like no other period in the history of our Society. The COVID-19 Pandemic led to the cancellation of both the MSTS 2020 Specialty Day in March in Orlando, and the in-person MSTS Annual Meeting in Columbus, Ohio in October. The tremendous leadership of our President, Dr. Joel Mayerson, and of our President-Elect, Dr. Carol Morris, has offset the loss of revenue from these meetings. With quick action, graciousness and top-notch negotiation skills, the direct costs of these cancellations have been limited to negligible amounts. A big shout out to our management team, Kerri Mink and Deborah Meyer for their expert assistance.

The Hatcher and General investment fund

portfolios have weathered the economic storm well and have recovered almost all value that was lost in the early months of spring. The overall very good fiscal health of the Society has provided a critical buffer during these uncertain times. The Research Funds provided by Dr. Matt DiCaprio through Sarcoma Strong remain robust and the Virtual Fun Run this year will push forward towards even higher levels of research support. However, individual donations to MSTS, either directly or through OREF, continue to be modest and I encourage all members to consider supporting our Society so that we can provide the membership value that you deserve and be prepared to weather any future storms.

On a positive note, I am happy to report that the following sponsors have committed to virtual sponsorship of our online Annual Meeting in October 9, 2020 – Onkos, DSI, Inc., Stryker, BioComposites, Implantcast North America, Med Learning Group and LinkBio. In addition, the auditing firm of Kutchins, Robbins and Diamond Ltd. has found the MSTS financial statements as of December 31, 2019 and 2018 to be in order.

I look forward to presenting to you the details of our Society's financial statements during the Business Session of our virtual Annual Meeting in October!

Musculoskeletal Tumor Registry Update – by Ben Miller, MD

This spring, the Musculoskeletal Tumor Registry (MsTR) completed the 6-center pilot trial. The trial was successful, and resulted in a concise data dictionary of relevant demographic and clinical factors for extremity sarcoma patients, an Electronic Health Record "smartform" template, and an understanding of the common challenges and barriers to institutional enrollment and participation.

The MsTR is now officially included in the AAOS Family of Registries and is supported and monitored by the Registry Oversight Committee along with the American Joint Replacement Registry (AJRR), the Shoulder and Elbow Registry (SER), the American Spine Registry (ASR), and the newly-formed Fracture and Trauma Registry (FTR). We have recruited a steering com-

mittee, made of MSTS members, to help lead the MsTR through the next phase of development. The next two years will mark significant growth and maturation of this effort, as we increase the amount of participating institutions and patient data, analyze the data recorded, and begin to look into questions of clinical importance.

This year, we are also beginning to expand the registry to capture more than just extremity sarcoma. We plan to work with the American Spine Registry to create a mechanism to capture spine tumors, and are in the early stages of creating a module for metastatic disease of bone. These additions will increase the relevance and visibility of this registry effort, and open additional opportunities for research, quality improvement, and advocacy.

The MSTS has been incredibly supportive of the MsTR from its inception. The society and its members were there from the beginning, starting with an OREF/MSTS grant that supported the pilot trial. Currently, 17 institutions have completed or are in contracting and 53 additional sites have expressed interest in joining. The MsTR is currently open for enrollment for all interested institutions – the process works best if an MSTS member serves as a "surgeon champion" to connect their hospital's administration with the AAOS registry staff, who will then begin the contracting process.

If you are interested in learning more about the MsTR, please contact Registry-Info@aaos.org.

MSTS Executive Committee

President

Joel Mayerson, MD
joel.mayerson@osumc.edu

President-Elect

Carol D. Morris, MD
cmorri61@jhmi.edu

Secretary

Michael P. Mott, MD
mmott2@hfhs.org

Treasurer

Michelle Ghert, MD
ghertm@mcmaster.ca

Immediate Past President

R. Lor Randall, MD, FACS
rlrandall@ucdavis.edu

Past President

Joseph Benevenia, MD
benevejo@rutgers.edu

Education Committee

Valerae O. Lewis, MD
volewis@mdanderson.org

Research Committee

Francis Young Lee, MD, PhD
francis.lee@yale.edu

Membership Committee

Brian Brigman, MD
brian.brigman@duke.edu

Members-at-Large

Lukas Nystrom, MD
nystrol@ccf.org

Gary E. Friedlaender, MD
gary.friedlaender@yale.edu

ELEOS™

Limb Salvage System

Helping to address the clinical challenges of limb salvage

Introducing the NEW ELEOS Proximal Femur

Supporting soft tissue apposition and backed by personalized planning to reduce the complexity of proximal femoral reconstruction.

Features Include:



Anatomically aligned suture holes

Provide directional attachment of adjacent soft tissues



Plasma sprayed surface

Located laterally to support soft tissue apposition



Supported by uDesign™ on-Demand personalized planning platform

Digital, personalized surgical plan based on individual surgeon needs

Contact us to learn more:

973.264.5400 | onkossurgical.com

Disclaimer: A surgeon should rely exclusively on his or her own professional medical/clinical judgment when deciding which particular product to use when treating a patient. ONKOS SURGICAL does not prescribe medical advice and advocates that surgeons be trained in the use of any particular product before using it in surgery. A surgeon must always refer to the product label and/or instructions for use before using any ONKOS SURGICAL product.

ONKOS SURGICAL, ELEOS and uDesign are registered marks and trademarks of ONKOS SURGICAL. © 2020 ONKOS SURGICAL. All rights reserved. CORP 09.23.20 v0

Precision Orthopedic Oncology

- ELEOS™ Limb Salvage Solutions
- My3D™ Personalized Solutions
- GenVie™ Regenerative Biologics



PROXIMAL FEMUR MEGASYSTEM - C

FINE TUNING WITHOUT THE LIMITATION OF A MORSE TAPER

Up to 3cm of height adjustment after implantation

Cemented & "Tapered Cone" Cementless stem options

Bone loss managed in 10mm segments

Tubular tooth junction enables fine tuning without limitations of a morse taper

3 decades with no reported fractures at the modular junction



LinkOncology.com | info@LinkBio.com

2020 Dues Renewal

Friendly Reminder –
Please submit payment for your 2020 membership dues. Pay your 2020 Membership Dues [online](#).

Forgot your login information?
Contact MSTs for assistance at 847/698-1625 or info@msts.org.

Thank you Donors!

Megan E. Anderson, MD, FAAOS
Donald M. Arms, MD
Felix H. Cheung, MD, FAAOS
Richard W. Churchill
Gary E. Friedlaender, MD, FAAOS
Mark C. Gebhardt, MD, FAAOS
Carrie L. Heincelman, MD
Bruce Jackson

Joseph M. Lane, MD, FAAOS
Patrick J. Murphy
Mary I. O'Connor, MD, FAAOS
Robert H. Quinn, MD, FAAOS
Nicholas Tedesco, DO, FAAOS
Judith Webb
Kristy L. Weber, MD, FAAOS

MSTS Donations YTD in 2020 as of 8.3.2020

Evidence Based Medicine Committee – Felasfa Wodajo, MD, Chair

The EBM Committee continues to work on internal projects as well as collaborate with other medical and surgical societies. This multidisciplinary approach allows us to share ideas and increase the visibility of our society.

The MSTS Guideline on the treatment of metastatic carcinoma in the femur completed peer and public review and has been approved by all three participating organizations. It will next be published, likely simultaneously, on the MSTS website and the Journal of Clinical Oncology. Thank you to the many MSTS members who submitted thoughtful comments.

The guideline (full title “Clinical Practice Guideline (CPG) for Medical, Radiation and Surgical Treatment of Metastatic Carcinoma and Myeloma of the Femur”) was led by MSTS as a three way collaboration with the American Society of Radiation Oncology (ASTRO) and American Society of Clinical Oncology (ASCO), each of whom contributed members to the workgroup.

The Principal Investigators are Felasfa Wodajo and Patrick Getty.

An multidisciplinary guideline project led by ASTRO on radiation therapy for soft tissue sarcoma has finished its literature survey and begun the writing phase. Steve Thorpe, a member of the Evidence Based Medicine Committee, is representing MSTS. Other MSTS members will be involved in the peer-review process.

We have two ongoing collaborations with the American College of Radiology (ACR) to develop structured reporting for musculoskeletal imaging. RADS stands for Reporting and Data Systems. MSTS members may already have seen structured reporting for lung, prostate and breast imaging, i.e. “lung RADS”, “PI RADS” and “BI RADS”, respectively. These tools are very helpful in providing more legible reporting of imaging findings and risk stratification.

Eric Henderson, a previous member of the EBM Committee, as well as other

MSTS members collaborated in an ACR workgroup to develop a “Bone RADS” for structured reporting of bone radiology. This project is nearing completion. ACR has committed to another musculoskeletal radiology RADS project, this time for structured reporting of soft tissue lesions. As before, they will include orthopedic oncologists in the workgroup.

Other collaborations are in various stages. These include potential projects with ASCO on chemotherapy for soft tissue sarcoma, and Society of Surgical Oncology (SSO) on inappropriate excisions of soft tissue sarcoma. We hope to provide updates on these and other projects in future newsletters.

The EBM committee serves the MSTS membership. If you have any ideas for guidelines or other quality improvement projects, please do not hesitate to reach out to myself (wodajo@sarcoma.md) or any EBM committee members.

Practice Management Committee – Adam S. Levin, MD, Chair

The last few months have presented great challenges for all of us – ourselves, our families, our patients, and our hospitals. As we have all worked hard to reorganize our orthopaedic practices in a safe and effective manner, I am sure that most our organizations have increasingly recognized the high level of importance of our clinical care. Whether with surgical management of sarcomas, treatment of metastatic disease, or follow up surveillance via telemedicine, our oncologic care has continued throughout this COVID-19 pandemic.

The Practice Management Committee has partnered closely with the AAOS to provide resources for our members regarding COVID-19 practice considerations, particularly regarding telehealth services. The Public Health Emergency declaration has afforded opportunities to expand telehealth offerings, including easing of origination site restrictions, reimbursement at in-office levels, and allowing states to relax licensing restrictions across state lines, among others. At the time of writing this newsletter, the Public Health Emergency is set to expire on July 25. However, the Department of Health and Human Services

has announced that it intends to extend that for 90 more days, which will likely continue CMS’s current regulatory environment until at least October.

Nonetheless, our members should be aware that some states have started to reassess their interstate licensure requirements. Similarly, some insurers have announced upcoming changes to their reimbursement for remote encounters, particularly regarding telephone-only encounters, starting July 25. Continue attention to state medical boards and local coverage determinations will be key over the coming months. We will work with the MSTS leadership to ensure that major updates from HHS and CMS will be distributed to our members.

It appears as though CMS is planning to proceed with the recommended changes regarding documentation and coding of outpatient Evaluation and Management codes starting January 1, 2021. Since this may have a profound effect on all of our practices, we are preparing a coding workshop together with Karen Zupko in October to coincide with the Annual Meet-

ing. Since this will now be virtual, we are adjusting our schedule accordingly. Registration information is open until October 9th. [Click here to register online.](#)

In addition, prior to the pandemic, we performed a survey of the MSTS membership regarding practice organization, administrative responsibilities, clinical expectations, and compensation. We want to thank all of those who participated in this important effort. We will be disseminating these findings to our members. It is amazing and humbling, though not surprising, the outsized role that many in our organization have within their practices and institutions.

In that light, I hope that all have been (and remain) safe and well through this period. Further, as many have recognized at high administrative levels the impact that COVID-19 has had on their practices, departments, and their healthcare organizations, we would encourage all to reach out to see what we can do to help investigate or mitigate those factors to suit your needs and interests.

New Agents for the Management of

TENOSYNOVIAL GIANT CELL TUMOR:

A Virtual Reality Tour of CSF1 Pathway Inhibitors

Med Learning Group presents a virtual reality tour exploring the role of CSF1 in the pathogenesis of TGCT and the mechanism of action of pexidartinib.

Follow the link below to view the animations. Free CME/CE credit is available after viewing the animations, and completing pre- and post-test questions, and the evaluation form.

[HTTP://WWW.MLG-TGCT.COM/](http://www.mlg-tgct.com/)



UMA



UMA



This activity is provided by Med Learning Group.

This activity is co-provided by Ultimate Medical Academy/Complete Conference Management (CCM).

This activity is provided with an educational grant from Daiichi Sankyo.

President's Report, cont'd from pg. 1

ety, and Ruth Jackson Orthopedic Society for office space. This agreement will go into effect in April 2021. We have spent many hours making sure we have the arranged the best management system that we can afford and retained our outstanding current staff leaders to assure continuity into the future.

6

Our Committee chairs always have been working incredibly hard to continue to develop new and exciting programs and information. The Education Committee is finalizing the Orthopedic Video Theater with the AAOS. I look forward to sharing all of the important things our Executive Committee has been working on to keep the MSTs moving forward during these challenging times at the Virtual

Annual Business Meeting on October 9, 2020. Please make sure your registration is complete so you can hear this update firsthand. I am honored to have served you as MSTs President this past year and look forward to a time when we can all be together again.

With warm regards,
Joel

Sarcoma Strong Corner – Matthew R. DiCaprio, MD

By April it was clear that any large-scale event would not be taking place in 2020. So, we pivoted our mission at Sarcoma Strong to a Global Initiative of engagement and increasing awareness. Many of our loyal sponsors were hit hard financially because of the Covid-19 Pandemic and we needed to refocus our 2020 goals. As John Heywood is famous for saying, “Many hands make light work.” The goals shifted to spreading the word about SarcomaStrong, increasing our social media presence and having teams of healthcare providers, patients and families from all over the world participate in this year’s event. By the end of July, we had teams from over 10 countries and 25 Sarcoma centers across America.

The AAOS social media team helped spread our message during July – Sarcoma Awareness Month.

Our first research grant recipient in 2017, Dr. Bang Hoang, completed his funding cycle towards the end of 2019. He was recently interviewed by SarcomaStrong to give feedback on his research findings and future grant opportunities. To see his comments, visit www.sarcomastrong.com/

research-supported-by-sarcoma-strong/. Our 2019-2020 MSTs Mentored Research Award recipient, Dr. Rosanna Wustrack, has completed the first of two aims of her study. The first aim was to collect fresh undifferentiated pleomorphic sarcoma (UPS) specimens and characterize the host immune response. Her team was able to successfully identify the tumor infiltrating immune cell subsets in 20 freshly resected extremity UPS specimens. Lymphocytes represented a greater proportion of the immune cell population in smaller tumors compared to larger tumors; specifically, CD8+ T cells were seen at a lower frequency in the tumors greater than 8cm compared to those less than 8cm. As patients with high grade tumors greater than 8cm historically have had worse outcomes, this data shows that the host immune environment may play a role in these clinical outcomes and could be a future target for sarcoma immunotherapy. The pandemic slowed their progress on their second aim to develop an immunocompetent sarcoma mouse model, then treat the sarcomas with high intensity focused ultrasound, and then evaluate the post-treatment immune profile.



The MSTs Fundraising Project Team continues to brainstorm ideas to grow our fundraising efforts to be self-sustaining. Many of the suggestions from team leaders focus on an event at our MSTs annual meeting. A golf outing, a mini triathlon (possibly with teams from different sarcoma centers, regions of the US, or fellowship programs), a fitness challenge, and/or a fundraising dinner or cocktail hour with industry sponsorship. We continue to explore merchandising options to add another source of revenue.

To all of the centers who formed teams, thank you! Together we are Uniting the Sarcoma Fight, raising awareness, and supporting research for enhanced knowledge and the hope of better, less toxic treatments. Any member who would like to join our mission, has new ideas to increase our impact, comments or concerns please email dicaprm@amc.edu or visit www.sarcomastrong.com.





Advancing care. **Inspiring hope.**

Sarcoma can affect anyone, from children to seniors and everyone in between. That's why we set the standard for modular implants that address the needs of a wide range of patients.

For more than 40 years, we've offered implant solutions to surgeons who treat patients facing sarcoma, and we're committed to continuing this legacy of innovation and care.

Learn more at [stryker.com](https://www.stryker.com)

The information presented is intended to demonstrate the breadth of Stryker's product offerings. A surgeon must always refer to the package insert, product label and/or instructions for use before using any of Stryker's products. Products may not be available in all markets because product availability is subject to the regulatory and/or medical practices in individual markets. Please contact your sales representative if you have questions about the availability of products in your area.

A surgeon must always rely on his or her own professional clinical judgment when deciding whether to use a particular product when treating a particular patient. Stryker does not dispense medical advice and recommends that surgeons be trained in the use of any particular product before using it in surgery.

Stryker Corporation or its divisions or other corporate affiliated entities own, use or have applied for the following trademarks or service marks: Stryker. All other trademarks are trademarks of their respective owners or holders.

Research Committee – Francis Young Lee, MD, PhD, Chair

The Research Committee is pleased to announce the following research opportunity in collaboration with the Sarcoma Strong Foundation.

I. Key Dates

- RFA Release Date: August 14, 2020
- Letter of Intent/Inquiry: October 15, 2020 (Not mandatory)
- Application Deadline: January 15, 2021 (pdf file to info@msts.org)
- Peer Review: January/February 2021
- Funding Decision: March/April 2021
- Start Date: May 1, 2021
- End Date: April 30, 2021 (No Cost Extension is possible until April 30, 2022)
- Progress Report: November 2021 (Presentation at Annual Meeting or Executive Committee)
- Final Report: 2022 Specialty Day / Executive Committee (Presentation)

II. Program Description

With a strong commitment from Dr. Matthew DiCaprio, the Sarcoma Strong Foundation will support MSTs to provide a \$50,000 one-year grant for the most impactful research related to sarcoma. The field of oncology has been rapidly evolving over the past 5 years. This is evidenced by the 2018 Nobel Prize in Medicine and Physiology that was awarded jointly to James P. Allison and Tasuku Honjo “for their discovery of cancer therapy by inhibition of negative immune regulation.” MSTs and Sarcoma Strong Foundation recognize the urgent need to provide MSTs members with just-in-time research opportunities in highly mechanistic biologic sarcoma research by adopting recent advances in immune-check points, oncogenic signaling, novel targeted therapies, RNA sequencing, circulating cancer cells, precision medicine, and other contemporary research concepts. Descriptive research on data collection or comparative studies, will be of less priority.

III. Eligibility

Assistant or Associate Professors at organizations with appropriate research infrastructure in U.S. Recipients of prior MSTs Grants or major NIH/NCI/DOD/National Research Council Canada will not be eligible.

IV. Grant Format and Page-Limits

(Arial font Size 11; 0.5 inch Margin Top, Bottom, Right, Left)

- Cover Page (SF 424 R&R form; <https://www.grants.gov/web/grants/forms/r-r-family.html>)
- NIH-format 5 page Biosketches for PI and other Co-Investigators (Samples and Forms are available @ <https://grants.nih.gov/grants/forms/biosketch.htm>)
- 1 Page Specific Aim Page
- Up to 12 Page Research Plan including Figures (Significance, Innovation, Approach including Preliminary Data)
- Literature Cited; IRB; IACUC; Letters; Other Forms (Not included in the Page Limit)
- IACUC/IRB: Certificate not required now; Just-in-Time for the approved grant by July 15, 2019.

V. Review Criteria & Peer Review

NIH/OREF Review Format: Overall Impact (Significance; Innovation; Investigators; Approach; Environment). The proposal will be reviewed by established investigators with prior federal funding history.

VI. Inquiries

Francis Y. Lee, M.D., Ph.D., Research Committee Chair (info@msts.org)

MSTS 2020 Mentored Research and Scholar Development Award

MSTS is enthusiastic about nurturing a culture of discovery and fostering mentorship for our society. MSTs is pleased to once again offer a Mentored Research and Scholarship Development Program Award of up to \$25,000. The purpose of the award, is to foster mentorship, enhance collaborative research and facilitate career advancement for young MSTs Candidate/Associate/Full Members. The submission deadline for applications is January 15, 2021. Don't miss this great opportunity. Please [click here](#) for further information on award description and sample grants..

Release Date: August 14, 2020
Letter of Interest/Inquiry: October 15, 2020 (Not Mandatory)
Grant Receipt Date: January 15, 2021
Peer Review Date: January-February, 2021
Executive Committee Review: March/April, 2021
Earliest Award Start Date: May 1, 2021
Award Amount: up to \$25,000.00
Award Number: MSTs-MRSDPA2
Award Duration: One year (May 2021-Apr, 2022)
No-Cost-Extension to Second Year is allowed.

Submission of Applications: Applications in a PDF format; info@msts.org
Inquiries: Francis Y. Lee, M.D.,
Research Committee Chair,
info@msts.org

Find out more online at:
<http://www.msts.org/index.php/research>



2020 Virtual Annual Meeting – Friday, October 9, 2020

Registration is open for the 2020 Virtual Annual Meeting. We hope you will join us. This is available free of charge to members and \$50 to non-members. [Register online here.](#)

MSTS 2020 Virtual Annual Meeting – Scientific Session Agenda
Friday, October 9, 2020 from 12:00 pm - 3:00 pm CT

Time	Presentation/Topic	Presenter
12:00 pm – 12:03 pm	Welcome – Introductions	Joel Mayerson, MD, MSTS President
12:03 pm – 12:05 pm	Meeting Overview	Thomas J. Scharschmidt, MD and Kurt Weiss, MD, Program Co-Chairs
12:05 pm – 12:11 pm	Presentation #1 Soft Tissue Sarcoma Subtypes Associated with Metastasis to Bone at Diagnosis: Another Application for the RACE (Rhabdomyosarcoma, Angiosarcoma, Clear Cell Sarcoma, Epithelioid Sarcoma) Mnemonic	Christopher Collier, MD
12:11 pm – 12:14 pm	Moderated Discussion /Questions	Thomas J. Scharschmidt, MD and Kurt Weiss, MD, Program Co-Chairs
12:14 pm – 12:20 pm	Presentation #2 Recruitment Patterns in a Large International Randomized Controlled Trial of Perioperative Care in Cancer Patients	Aaron Gazendam, MD
12:20 pm – 12:23 pm	Moderated Discussion/Questions	Thomas J. Scharschmidt, MD and Kurt Weiss, MD, Program Co-Chairs
12:23 pm – 12:29 pm	Presentation #3 Short Term Infectious Complications with Transdermal “Osseointegrated” Implants	Colin Harrington, MD
12:29 pm – 12:32 pm	Moderated Discussion/Questions	Thomas J. Scharschmidt, MD and Kurt Weiss, MD, Program Co-Chairs
12:32 pm – 12:52 pm	Product Theater #1 – Onkos Surgical Supporting Soft Tissue Apposition and Attachment in Proximal Femoral Replacement Surgery	Joel Mayerson, MD
12:52 pm – 12:58 pm	Presentation #4 Update on the Combined MSTS-ACR Bone Tumor Radiology Reporting and Data Systems (RADS)	Eric R. Henderson, MD

Time	Presentation/Topic	Presenter
12:58 pm – 1:01 pm	Moderated Discussion/Questions	Thomas J. Scharschmidt, MD and Kurt Weiss, MD, Program Co-Chairs
1:01 pm – 1:07 pm	Presentation #5 The Musculoskeletal Tumor Registry: Lessons, Barriers, and Future Goals	Benjamin J. Miller, MD, MS
1:07 pm – 1:10 pm	Moderated Discussion/Questions	Thomas J. Scharschmidt, MD and Kurt Weiss, MD, Program Co-Chairs
1:10 pm – 1:30 pm	Product Theater #2 – DSI, Inc. Innovative Treatment in Diffuse Pigmented Villonodular Synovitis (PVNS)/Tenosynovial Giant Cell Tumor (TGCT)	R. Lor Randall, MD, FACS
1:30 pm – 1:36 pm	Presentation #6 The Interaction of Skp2 with P27 Enhances in the Progression and Tumor-Initiating Properties of Osteosarcoma	Jichuan Wang, MD
1:36 pm – 1:39 pm	Moderated Discussion/Questions	Thomas J. Scharschmidt, MD and Kurt Weiss, MD, Program Co-Chairs
1:39 pm – 1:50 pm	Review of Submissions and Wrap Up	Thomas J. Scharschmidt, MD and Kurt Weiss, MD, Program Co-Chairs
1:50 pm – 3:00 pm	MSTS Member Business Meeting	Joel Mayerson, MD, MSTS President See separate agenda – No CME credit for Business Meeting attendance

CODING COURSE

Thursday, October 15, 2020

We are collaborating with Karen Zupko Associates again to provide an updated Coding Course on Thursday, October 15, 2020 from 5:30 – 8:30 pm CT. Register online for the Coding Course [here](#).

In this three-hour session, delivered live via webinar, Sarah Wiskerchen, MBA, CPC will cover

- E/M “1.0” – Recap of E/M level and category criteria that apply in 2020, and will still be used for selected E/M services in 2021
- E/M “2.0” – In depth review of E/M criteria changes that will apply in 2021
- Comparison of 2020 and 2021 E/M coding systems using musculoskeletal tumor examples

The session includes a resource workbook that will be shipped to registrants in advance of the webinar.

This live session includes interactive time for questions and answers.

Your Instructor

Sarah Wiskerchen, MBA, CPC of KarenZupko & Associates, Inc. presents on CPT and ICD-10 coding for the AAOS national workshop series. State specialty societies, physical therapy firms and large musculoskeletal groups have invited Sarah to educate physicians and staff. She is actively working with her orthopaedic clients to prepare for the 2021 E/M coding and documentation requirements.

In addition to coding education, Sarah’s consulting projects include E/M and surgical auditing, overall practice evaluations, and redesigning billing processes for increased collection effectiveness.



Sarah Wiskerchen, MBA, CPC

What could less tumor mean for your TGCT (PVNS/GCT-TS) patients?

Learn more at our upcoming virtual theater on
October 9, 1:10-1:30 PM CST

Innovative treatment in diffuse pigmented villonodular synovitis (PVNS)/tenosynovial giant cell tumor (TGCT)

Presented by:

R. Lor Randall, MD, FACS

Professor and Chair

UC Davis Department of Orthopedic Surgery

The David Linn Endowed Chair in Orthopedic Surgery

UC Davis Comprehensive Cancer Center

TGCT, tenosynovial giant cell tumor; PVNS, pigmented villonodular synovitis;
GCT-TS, giant cell tumor of the tendon sheath.



implantcast

NORTH AMERICA




Contact us to learn more
about the MUTARS[®] silver
or LUMiC[®] pedestal cup.

info@implantcast-na.com
implantcast-na.com

These devices are not 510k cleared in the U.S.

A surgeon should use his or her best judgement to determine which product to use to treat a patient. Contact us to learn about availability of these products in your area. Registered marks and trademarks are the property of Implantcast[®] GmbH.



STIMULAN®

POWER TO TRANSFORM™

Perfect partner for your cases with an infected site



- ✓ Cleared for placement directly at site of infection
- ✓ Controlled purity
- ✓ Truly absorbable at an optimal rate
- ✓ No third body damage

Discover the true potential at Biocomposites.com



This advert may include the use of STIMULAN or techniques that go beyond the current clearance / approval granted by the relevant regulatory authority. Please contact your local representative for further information.


©2019, All rights reserved. No unauthorized copying, reproduction, distributing or republication is allowed unless prior written permission is granted by the owner, Biocomposites Ltd. Patents granted: GB2367552, EP 1204599 B1, US 6780391, EP 2594231 B1, US 8883063, CN ZL20121046617.X, GB2496710, EP 3058899 B1. Patents pending: GB1502655.2, US 15/040075, CN 201610089710.5, US 15/288328, GB1704688.9, EP 18275044.8, US 15/933936, CN 108619579A.

See Biocomposites.com for further information. MA0253R2

Webinar Series

With the Annual Meeting going virtual this year, the Education Committee has been busy creating a webinar series for membership. There will be a series of 6 webinars over the next year - the first taking place on October 21, 2020 and focusing on Barriers to Care Caused by COVID-19. Registration is free to members and non-members can register for \$10. The entire series is exclusively supported by Stryker.

[Click here to register.](#)



OUR MISSION

The Musculoskeletal Tumor Society will advance the science of orthopaedic oncology and promote high standards of patient care through excellence in education and research.

OUR VISION

The Musculoskeletal Tumor Society will be a recognized authority on all aspects of orthopaedic oncology, an influential participant in policy-making for orthopaedic oncology services, and responsive to the needs of orthopaedic oncologists and their patients.